| 2023 | Preventive effect of empagliflozin and ezetimibe on hepatic steatosis in adults and murine models
| BIOMEDICINE & PHARMACOTHERAPY |
| 2023 | Sorafenib versus nivolumab after lenvatinib treatment failure in patients with advanced hepatocellular carcinoma | EUROPEAN JOURNAL OF GASTROENTEROLOGY & HEPATOLOGY |
| 2023 | Suboptimal Performance of Hepatocellular Carcinoma Prediction Models in Patients with Hepatitis B Virus-Related Cirrhosis
| DIAGNOSTICS |
| 2023 | Integrative analysis of multiple genomic data from intrahepatic cholangiocarcinoma organoids enables tumor subtyping
| NATURE COMMUNICATIONS |
| 2022 | ALT Is Not Associated With Achieving Subcirrhotic Liver Stiffness and HCC During Entecavir Therapy in HBV-Related Cirrhosis | CLINICAL GASTROENTEROLOGY AND HEPATOLOGY |
| 2022 | Applications of molecular barcode sequencing for the detection of low-frequency variants in circulating tumour DNA from hepatocellular carcinoma | LIVER INTERNATIONAL |
| 2022 | Identification of a distinct NK-like hepatic T-cell population activated by NKG2C in a TCR-independent manner
| JOURNAL OF HEPATOLOGY |
| 2022 | Clinical characteristics and prognosis of Korean patients with hepatocellular carcinoma with respect to etiology
| Journal of Liver Cancer(대한간암학회지) |
| 2022 | Fibrotic Burden Determines Cardiovascular Risk among Subjects with Metabolic Dysfunction-Associated Fatty Liver Disease
| GUT AND LIVER |
| 2022 | Co-administration of ursodeoxycholic acid with rosuvastatin/ezetimibe in a non-alcoholic fatty liver disease model
| GASTROENTEROLOGY REPORT |
| 2022 | Prevalence and Risk Factors of Cardiovascular Disease in Patients with Chronic Hepatitis B | DIGESTIVE DISEASES AND SCIENCES |
| 2022 | Anti-Cancer Effects of YAP Inhibitor (CA3) in Combination with Sorafenib against Hepatocellular Carcinoma (HCC) in Patient-Derived Multicellular Tumor Spheroid Models (MCTS)
| CANCERS |
| 2022 | Liver-Directed Concurrent Chemoradiotherapy versus Sorafenib in Hepatocellular Carcinoma with Portal Vein Tumor Thrombosis
| CANCERS |
| 2022 | Probability of HBsAg loss after nucleo(s)tide analogue withdrawal depends on HBV genotype and viral antigen levels
| JOURNAL OF HEPATOLOGY |
| 2022 | KASL clinical practice guidelines for management of chronic hepatitis B
| CLINICAL AND MOLECULAR HEPATOLOGY |
| 2022 | Comparison of FibroScan-Aspartate Aminotransferase (FAST) Score and Other Non-invasive Surrogates in Predicting High-Risk Non-alcoholic Steatohepatitis Criteria
| FRONTIERS IN MEDICINE |
| 2022 | Predictive Performance of CAGE-B and SAGE-B Models in Asian Treatment-Naive Patients Who Started Entecavir for Chronic Hepatitis B | CLINICAL GASTROENTEROLOGY AND HEPATOLOGY |
| 2022 | Prediction of Sustained Response After Nucleo(s)tide Analogue Cessation Using HBsAg and HBcrAg Levels: A Multicenter Study (CREATE)
| CLINICAL GASTROENTEROLOGY AND HEPATOLOGY |
| 2022 | Long-term renal safety between patients with chronic hepatitis B receiving tenofovir vs. entecavir therapy: A multicenter study | JOURNAL OF VIRAL HEPATITIS |
| 2022 | Cardiovascular Risk Is Elevated in Lean Subjects with Nonalcoholic Fatty Liver Disease
| GUT AND LIVER |
| 2022 | Impaired antibacterial response of liver sinusoidal Vγ9 + Vδ2 + T cells in patients with chronic liver disease | GUT |
| 2022 | Predictors of Sarcopenia in an Obese Asian Population | NUTRITION AND CANCER-AN INTERNATIONAL JOURNAL |
| 2022 | A micellized bone morphogenetic protein-7 prodrug ameliorates liver fibrosis by suppressing transforming growth factor- β signaling
| AMERICAN JOURNAL OF CANCER RESEARCH |
| 2022 | External Validation of the FSAC Model Using On-Therapy Changes in Noninvasive Fibrosis Markers in Patients with Chronic Hepatitis B: A Multicenter Study
| CANCERS |
| 2022 | Validation of PH and Varices Risk Scores for Prediction of High-Risk Esophageal Varix and Bleeding in Patients with B-Viral Cirrhosis
| DIAGNOSTICS |
| 2022 | Episodic Detectable Viremia Does Not Affect Prognosis in Untreated Compensated Cirrhosis With Serum Hepatitis B Virus DNA <2,000 IU/mL | AMERICAN JOURNAL OF GASTROENTEROLOGY |
| 2022 | Increased prevalence rate of metabolic syndrome is an independent predictor of cardiovascular disease in patients with antineutrophil cytoplasmic antibody-associated vasculitis | RHEUMATOLOGY INTERNATIONAL |
| 2022 | Regression of liver fibrosis and hepatocellular carcinoma development after HCV eradication with oral antiviral agents
| SCIENTIFIC REPORTS |
| 2022 | Validation of Pre-/Post-TACE-Predict Models among Patients with Hepatocellular Carcinoma Receiving Transarterial Chemoembolization
| CANCERS |
| 2022 | Long-term effects of entecavir and tenofovir treatment on the fibrotic burden in patients with chronic hepatitis B | JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY |
| 2022 | Transarterial Radioembolization for Unresectable Hepatocellular Carcinoma: Real-Life Efficacy and Safety Analysis of Korean Patients
| CANCERS |
| 2021 | Besifovir dipivoxil maleate: a novel antiviral agent with low toxicity and high genetic barriers for chronic hepatitis B | EXPERT OPINION ON PHARMACOTHERAPY |
| 2021 | Novel Liver Stiffness-Based Nomogram for Predicting Hepatocellular Carcinoma Risk in Patients with Chronic Hepatitis B Virus Infection Initiating Antiviral Therapy
| CANCERS |
| 2021 | No influence of hepatic steatosis on the 3-year outcomes of patients with quiescent chronic hepatitis B | JOURNAL OF VIRAL HEPATITIS |
| 2021 | YAP/TAZ Suppress Drug Penetration Into Hepatocellular Carcinoma Through Stromal Activation | HEPATOLOGY |
| 2021 | Dickkopf-1 promotes angiogenesis by upregulating VEGF receptor 2-mediated mTOR/p70S6K signaling in hepatocellular carcinoma
| AMERICAN JOURNAL OF CANCER RESEARCH |
| 2021 | Risk stratification using sarcopenia status among subjects with metabolic dysfunction-associated fatty liver disease
| JOURNAL OF CACHEXIA SARCOPENIA AND MUSCLE |
| 2021 | Risk assessment of hepatocellular carcinoma and liver-related events using ultrasonography and transient elastography in patients with chronic hepatitis B | JOURNAL OF VIRAL HEPATITIS |
| 2021 | Effect of tenofovir alafenamide vs. tenofovir disoproxil fumarate on hepatocellular carcinoma risk in chronic hepatitis B | JOURNAL OF VIRAL HEPATITIS |
| 2021 | Impact of tenofovir alafenamide vs. entecavir on hepatocellular carcinoma risk in patients with chronic hepatitis B | HEPATOLOGY INTERNATIONAL |
| 2021 | Treatment efficacy by hepatic arterial infusion chemotherapy vs. sorafenib after liver-directed concurrent chemoradiotherapy for advanced hepatocellular carcinoma | JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY |
| 2021 | Screening, confirmation, and treatment rates of hepatitis C virus infection in a tertiary academic medical center in South Korea | JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY |
| 2021 | Hepatic Decompensation in Cirrhotic Patients Receiving Antiviral Therapy for Chronic Hepatitis B | CLINICAL GASTROENTEROLOGY AND HEPATOLOGY |
| 2021 | Liver Stiffness-Based Risk Prediction Model for Hepatocellular Carcinoma in Patients with Nonalcoholic Fatty Liver Disease
| CANCERS |
| 2021 | Controlled attenuation parameter value and the risk of hepatocellular carcinoma in chronic hepatitis B patients under antiviral therapy | HEPATOLOGY INTERNATIONAL |
| 2021 | Pharmacokinetics and safety of evogliptin in hepatically impaired patients | BRITISH JOURNAL OF CLINICAL PHARMACOLOGY |
| 2021 | The efficacies of entecavir and tenofovir in terms of enhancing prognosis after curative treatment of hepatitis B virus-related hepatocellular carcinoma | EUROPEAN JOURNAL OF INTERNAL MEDICINE |
| 2021 | 다중유전자 위험점수를 이용한 비알코올 지방간질환에서 간세포암종 발생 예측 모델
| Korean Journal of Gastroenterology |
| 2021 | Direct-Acting Antivirals Improve Treatment Outcomes in Patients with Hepatitis C Virus-Related Hepatocellular Carcinoma Treated with Transarterial Chemoembolization: A Nationwide, Multi-center, Retrospective Cohort Study | DIGESTIVE DISEASES AND SCIENCES |
| 2021 | Dynamics of liver stiffness-based risk prediction model during antiviral therapy in patients with chronic hepatitis B | EUROPEAN JOURNAL OF GASTROENTEROLOGY & HEPATOLOGY |
http://orcid.org/0000-0001-6324-2224
(47861376300)
